Prenetics Global Limited
Prenetics Global Limited (PRE) Financial Performance & Income Statement Overview
Explore the financials of Prenetics Global Limited (PRE), including yearly and quarterly data on income, cash flow, and balance sheets.
Prenetics Global Limited (PRE) Income Statement & Financial Overview
Review Prenetics Global Limited PRE income statement with detailed quarterly and annual figures.
Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
---|---|---|---|---|
Revenue | $10.49M | $7.78M | $5.94M | $6.41M |
Cost of Revenue | $6.59M | $3.83M | $2.17M | $2.63M |
Gross Profit | $3.90M | $3.95M | $3.77M | $3.78M |
Gross Profit Ratio | $0.37 | $0.51 | $0.63 | $0.59 |
R&D Expenses | $2.58M | $2.59M | $3.03M | $2.73M |
SG&A Expenses | $19.18M | $13.12M | $12.10M | $10.96M |
Operating Expenses | $20.47M | $15.76M | $14.38M | $13.69M |
Total Costs & Expenses | $27.06M | $19.59M | $16.55M | $16.32M |
Interest Income | $2.04M | $0.00 | $0.00 | $0.00 |
Interest Expense | $78630.00 | $80552.00 | $27479.00 | $16339.00 |
Depreciation & Amortization | $0.00 | $0.00 | $1.10M | $1.72M |
EBITDA | -$24.89M | -$12.03M | -$9.51M | -$8.19M |
EBITDA Ratio | -$2.37 | -$1.55 | -$1.60 | -$1.28 |
Operating Income | -$16.57M | -$11.81M | -$10.61M | -$9.91M |
Operating Income Ratio | -$1.58 | -$1.52 | -$1.79 | -$1.54 |
Other Income/Expenses (Net) | -$8.40M | -$304854.00 | -$700171.00 | $595897.00 |
Income Before Tax | -$24.97M | -$12.11M | -$11.31M | -$9.09M |
Income Before Tax Ratio | -$2.38 | -$1.56 | -$1.90 | -$1.42 |
Income Tax Expense | -$7.42M | -$75307.00 | -$89234.00 | -$285938.00 |
Net Income | -$16.34M | -$10.67M | -$10.72M | -$8.57M |
Net Income Ratio | -$1.56 | -$1.37 | -$1.80 | -$1.34 |
EPS | $0.00 | -$0.84 | -$0.88 | -$0.70 |
Diluted EPS | $0.00 | -$0.84 | -$0.88 | -$0.70 |
Weighted Avg Shares Outstanding | $12.71M | $12.71M | $12.22M | $12.22M |
Weighted Avg Shares Outstanding (Diluted) | $12.71M | $12.72M | $12.22M | $12.22M |
Over the past four quarters, Prenetics Global Limited demonstrated steady revenue growth, increasing from $6.41M in Q1 2024 to $10.49M in Q4 2024. Operating income reached -$16.57M in Q4 2024, maintaining a consistent -158% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$24.89M, reflecting operational efficiency. Net income dropped to -$16.34M, with EPS at $0.00. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan